The discovery that HIV requires a chemokine co-receptor to invade host cells has prompted many investigations into therapeutic strategies that target these receptors in an attempt to block HIV entry. In this review, Scott Cairns and Patricia D'Souza discuss these potentially powerful approaches and how they complement existing antiretroviral drug therapy.